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INTRODUCTION
ESRD throughout the world: Morbidity, mortality, and
quality of life
Following the International Society of Nephrology and least debatable of all data as long as there is complete
meeting in Buenos Aires, with its broad range of nephrol- ascertainment. Morbidity is more difficult to measure
ogy topics, a large number of participants gathered at and may have multiple events (e.g., hospital admissions),
the Uruguayan seaside resort of Punta del Este to focus which provide for statistical challenges. Health-related
more specifically on issues related to end-stage renal quality of life may be the most complex of all measures,
disease (ESRD). We were able to assemble an ambitious but it is of great interest to clinicians and patients, partic-
program on “ESRD Throughout the World” with a su- ularly as an outcome of therapy.
perb panel of expert speakers. Our committee members The editor of Kidney International, Dr. Saulo Klahr,
(Appendix) deserve credit for assembling this program. has enthusiastically agreed to publish this peer-reviewed
One of our difficult tasks was to limit this program to a supplement issue of the proceedings for this meeting,
two-day meeting. We hope we struck a good balance of and Baxter Healthcare has sponsored this special issue.
covering the most important and relevant topics in the Throughout the world, there is clearly a lot of interest
limited time frame. in renal epidemiology and outcome issues. The meeting
The existence of numerous registries around the world itself could not have happened without the broad spon-
has made ESRD a well-studied chronic disease, particu- sorship by Latin American branches of pharmaceutical
larly in terms of epidemiology and clinical outcomes. It and dialysis companies.
has become the envy of most fields in medicine. We Our challenges are clearly set in the program. We
may already serve as a model for other disease-specific succeeded in encouraging all attendants to ask questions
scientific registries. No other field, perhaps with the ex- and had arranged for simultaneous translation through-
ception of the study of various cancers, has as much out the meeting to allow questions in either Spanish or
information that is population-based and allows for anal- English. We had interesting and constructive exchanges
yses of incidence, treatment, and outcomes issues. of opinions from the audience, which made this an excit-
We set the following goals for this symposium: 1) to ing and productive scientific meeting. In addition to the
review and compare various study approaches for ESRD lectures we accepted through peer review 34 abstracts
outcomes research; 2) to understand analytical pitfalls for poster presentations and formal poster discussions.
and biostatistical methods for ESRD research; 3) to eval- This supplement to Kidney International reflects most
uate the most recent results in morbidity and mortality of the invited lectures during this meeting. Some points
for groups of ESRD patients; 4) to consider quality of from the discussions have been incorporated into the
life as an important outcome of ESRD therapy; and 5) manuscripts. We thank all contributors and trust that
to assess the value and practicability of international this meeting will lead to further research in ESRD
comparisons and consider future studies. We wanted this throughout the world.
meeting to have practical relevance for the practicing
clinician, outcome researcher, and anyone involved in a
Friedrich K. Port, Stanley S.A. Fenton,national or regional registry. As a joint effort, we trust
and Nelson Mazzuchiwe can accomplish these goals both during the meeting
Guest Editors
and through publication of the key manuscripts in this
supplement to Kidney International.
We will therefore be dealing with many aspects of APPENDIX
epidemiology, methodological issues, registries, and out- Organizing Committee, Uruguay
comes, specifically related to mortality, morbidity, and
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